Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

Article Authors: Linda Morrow, Douglas B Muchmore, Elizabeth A Ludington, Daniel E Vaughn, Marcus Hompesch

no alt text set


This study was designed to test the hypothesis that co-administration of recombinant human hyaluronidase (rHuPH20) with regular insulin or insulin lispro will reduce intrasubject variability in pharmacokinetic end points compared with lispro alone.